Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2025 16:02 ET | Source: Spyre Therapeutics, Inc.

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Reported positive interim Phase 1 results for two next-generation TL1A antibodies, demonstrating both were well-tolerated, exhibited pharmacokinetic ("PK") profiles supporting quarterly or biannual...